We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Deal watch: High hopes for oral SYK inhibitor in rheumatoid arthritis.
- Authors
Flight, Monica Hoyos
- Abstract
The article reports on the licensing agreement between Portola Pharmaceuticals Inc. and Biogen Idec Inc. as an approach to develop and commercialize a novel oral spleen tyrosine kinase (SYK) inhibitor called PRT062607. It states that the drug development and commercialization will be headed by Portola while the global programme in major indications will be led by Biogen. It adds that the drug efficiency will result to its range uses in inflammatory conditions such as rheumatoid arthritis.
- Subjects
LICENSE agreements; PROTEIN-tyrosine kinase inhibitors; DRUG development; DRUG marketing; RHEUMATOID arthritis treatment; PORTOLA Pharmaceuticals Inc.; BIOGEN Inc. (2003- )
- Publication
Nature Reviews Drug Discovery, 2012, Vol 11, Issue 1, p10
- ISSN
1474-1776
- Publication type
Article
- DOI
10.1038/nrd3631